Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP
Registry-based study shows autologous and alloHSCT impact outcomes in relapsed nodular lymphocyte-predominant Hodgkin lymphoma.
Key Points
Evaluate the outcomes of allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory nodular lymphocyte-predominant Hodgkin lymphoma.
Included adult patients with NLPHL undergoing alloHSCT from 2010 to 2021
Reported outcomes included 5-year progression-free survival, overall survival, and relapse rates
Exclusion of untreated NLPHL and tandem auto-allo transplants
Median follow-up was 5 years; 5-year progression-free survival was 46.7%
5-year overall survival was 63.0% with a relapse incidence of 35.5%
Disease status at alloHSCT was the only significant prognostic factor for progression-free survival.